ISA-247. Calcineurin inhibitor, treatment of renal transplant rejection, treatment of psoriasis

Drugs of the Future

Volumn 29, Issue 7, 2004, Pages 680-686

  McIntyre, J A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

6 [3 HYDROXY 4 METHYL 2 (METHYLAMINO) 6,8 NONADIENOIC ACID]CYCLOSPORIN A; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYCLOSPORIN A; ISA 247; ISATX 247; R 1524; TACROLIMUS; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ANTIINFLAMMATORY ACTIVITY; BROMINATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG INDICATION; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; GASTROINTESTINAL SYMPTOM; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; IMMUNOPHARMACOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; KIDNEY GRAFT REJECTION; LYMPHOCYTE PROLIFERATION; MONKEY; NEPHROTOXICITY; NEUROLOGIC DISEASE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PHARMACODYNAMICS; PSORIASIS; REVIEW; SIDE EFFECT;

EID: 4644336659     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2004.029.07.819884     Document Type: Review

References (31)

1. Naicker, S., Yatscoff, R.W., Foster, R.T. (Isotechnika Inc.). Cyclosporine analogue mixtures and their use as immunomodulating agents. US 2003139326, WO 0333527.
2. Naicker, S., Yatscoff, R.W., Foster, R.T. (Isotechnika Inc.). Novel cyclosporin analog formulations. US 2003171264, WO 0332949.
3. Naicker, S., Yatscoff, R.W., Foster, R.T., Abel, M., Jayaraman, S., Mair, H.-J., Adam, J.-M., Lohri, B. (Isotechnika Inc.; F. Hoffmann-La Roche AG). Synthesis of cyclosporin analogs. US 2003212249, WO 0333526.
4. Hariharan, S., Johnson, C.P., Bresnahan, B.A., Taranto, S.E., McIntosh, M.J., Stablein, D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. New Engl J Med 2000, 342: 605-12.
5. Schreiber, S.L., Crabtree, G.R. The mechanism of action of cyclospohn A and FK506. Immunol Today 1992, 13: 136-42.
6. Clipstone, N.A., Crabtree, G.R. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992, 357: 695-7.
7. Cardenas, M.E., Zhu, D., Heitman, J. Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin. Curr Opin Nephrol Hypertens 1995, 4: 472-7.
8. Aspeslet, L., Freitag, D., Trepanier, D., Abel, M., Naicker, S., Kneteman, N., Foster, R., Yatscoff, R. ISATX247: A novel calcineurin inhibitor. Transplant Proc 2001, 33: 1048-51.
9. Abel, M.D., Aspeslet, L.J., Freitag, D.G., Naicker, S., Trepanier, D.J., Kneteman, N.M., Foster, R.T., Yatscoff, R.W. ISATX247: A novel calcineurin inhibitor. J Heart Lung Transplant 2001, 20(2): Abst 36.
10. Yatscoff, R.W., Foster, R.T., Naicker, S.A., Aspeslet, L.J., Abel, M.D., Freitag, D.G., Trepanier, D.J. ISATX247: Novel calcineurin inhibitor. 18th Int Congr Transplant Soc (Aug 27-Sept 1, Rome) 2000, 315.
11. Abel, M.D., Aspeslet, L.J., Freitag, D.G., Halloran, P.F., Kneteman, N.M., Naicker, S.S., Trepanier, D.J., Foster, R.T., Yatscoff, R.W. Preclinical efficacy of a novel calcineurin inhibitor: ISAtx247. Am J Transplant 2001, 1(Suppl. 1): Abst 1191.
12. Freitag, D.G., Abel, M.D., Aspeslet, L.J. et al. Development of the novel immunosuppressive agent ISATX247 using a pharmacodynamic approach. 42nd Annu Meet Soc Toxicol (March 9-13. Salt Lake City) 2003, Abst 18.
13. Maksymowych, W.P., Jhangri, G.S., Aspeslet, L., Abel, M.D., Trepanier, D.J., Naicker, S., Freitag, D.G., Cooper, B.L., Foster, R.T., Yatscoff, R.W. Amelioration of accelerated collagen induced arthritis by a novel calcineurin inhibitor, ISATX247. J Rheumatol 2002, 29: 1646-52.
14. Bîrsan, T., Dambrin, C., Villanueva, J.C., Yatscoff, R.W., Morris, R.E. Ex vivo evaluation of the immunosuppressive effect of the novel calcineurin inhibitor ISATX 247 on whole blood lymphocytes of non-human primates. Am J Transplant 2001, 1(Suppl. 1): Abst 1199.
15. Stalder, M., Bîrsan, T., Hubble, R.W., Paniagua, R.T., Morris, R.E. In vivo evaluation of the novel calcineurin inhibitor ISATX247 in non-human primates. J Heart Lung Transplant 2003, 22: 1343-52.
16. Stalder, M., Birsan, T., Hubble, R.W., Paniagua, R.T., Morris, R.E. In vivo evaluation of the novel calcineurin inhibitor ISATX247 in non-human primates. 19th Int Congr Transplant Soc (Aug 25-30, Miami) 2002, Abst 2032.
17. Gregory, C.R., Kyles, A.E., Bernsteen, L. et al. Compared to cyclosporine, ISATX247 significantly prolongs renal allograft survival in a nonhuman primate model. 19th Int Congr Transplant Soc (Aug 25-30, Miami) 2002, Abst 24.
18. Shapiro, A.M.J., Rajotte, R.J., Lakey, J.R.T., Bigam, D.L., Kneteman, N.M., Yatscoff, R.W. Prolonged islet allograft survival without toxicity using ISATx247, a novel calcineurin inhibitor. Am J Transplant 2001, 1(Suppl. 1): Abst 828.
19. Abel, M.D., Aspeslet, L.J., Freitag, D.G., Halloran, P.F., Kneteman, N.T., Naicker, S.S., Trepanier, D.J., Foster, R.T., Yatscoff, R.W. ISAtx247: A novel calcineurin inhibitor with minimal renal toxicity. Am J Transplant 2001, 1(Suppl. 1): Abst 1192.
20. Abel, M.D., Aspeslet, L.J., Broski, A.P., Freitag, D.G., Naicker, S.S., Trepanier, D.J., Foster, R.T., Yatscoff, R.W. Phase 2 trial results of ISAtx247, a novel calcineurin inhibitor, in renal transplantation. Am J Transplant 2002, 2(Suppl. 3): Abst 959.
21. Yatscoff, R.W., Abel, M.D., Aspeslet, L.J., Foster, R.T., Freitag, D.G., Huizinga, R.B., Mayo, P.R., Trepanier, D.J. Phase 2, randomized, multicenter, open-label study of ISA247 and Neoral(R) in post-renal transplant patients. Am J Transplant 2003, 3(Suppl. 5): Abst 1215.
22. Abel, M.D., Aspeslet, L.J., Foster, R.T., Huizinga, R.B., Freitag, D.G., Mayo, P.R., Trepanier, D.J., Yatscoff, R.W. Phase 2, randomized, multicenter, open-label study of ISA247 and Neoral(R) in post-renal transplant patients. 11th Congr Eur Soc Organ Transplant (Sept 20-24, Venice) 2003, Abst 106.
23. Mayo, P., Freitag, D., Boutouyrie-Dumont, B., Farhan, M. Pharmacokinetics and pharmacodynamics of ISA247 a new-generation calcineurin inhibitor in stable renal transplant patients. Am J Transplant, 2004, 4(Suppl. 8): Abst 1212.
24. Final phase IIa results from kidney transplant study of ISA-247. DailyDrugNews.com (Daily Essentials) June 11, 2003.
25. Phase II results announced for ISA-247 in psoriasis. DailyDrugNews.com (Daily Essentials) March 12, 2003.
26. FDA agrees to dose range finding study for ISA-247. DailyDrugNews.com (Daily Essentials) March 1, 2004.
27. Health Canada clears multiple dose range finding study for trans-ISA-247. DailyDrugNews.com (Daily Essentials) April 26, 2004.
28. Abel, M.D., Aspeslet, L.J., Broski, A.P., Freitag, D.G., Naicker, S.S., Trepanier, D.J., Foster, R.T., Yatscoff, R.W. Phase 1 and 2 clinical trial results of ISAtx247: A novel calcineurin inhibitor. 5th Int Conf New Trends Clin Exp Immunosuppr (Feb 7-10, Geneva) 2002, Abst 81.
29. Abel, M.D., Aspeslet, L.J., Freitag, D.G., Naicker, S., Trepanier, D.J., Kneteman, N.M., Foster, R.T., Yatscoff, R.W. ISATX247: A novel calcineurin inhibitor. J Heart Lung Transplant 2001, 20: 161.
30. Christians, U. Understanding mechanisms of toxicity of immunosuppressive drugs to improve their safety profiles and broaden the scope of use. 42nd Annu Meet Soc Toxicol (March 9-13, Salt Lake City) 2003, Abst 14.
31. Maksymowych, W.P., Aspeslet, L., Abel, M., Trepanier, D., Naiker, R., Freitag, D., Foster, R., Yatscoff, R.W. Amelioration of established collagen-induced arthritis by ISATX247, a novel calcineurin inhibitor. 2001 Innov Ther in Autoimmun Dis (March 8-10, San Francisco) 2001, Abst.